Finast: Clinically Proven 5α-Reductase Inhibition for Androgen-Related Conditions
| Product dosage: 1mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 60 | $1.73 | $104.06 (0%) | 🛒 Add to cart |
| 90 | $1.69 | $156.09 $152.22 (2%) | 🛒 Add to cart |
| 120 | $1.61 | $208.12 $193.50 (7%) | 🛒 Add to cart |
| 180 | $1.47 | $312.18 $264.88 (15%) | 🛒 Add to cart |
| 270 | $1.37
Best per pill | $468.27 $369.80 (21%) | 🛒 Add to cart |
| Product dosage: 5mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 30 | $2.24 | $67.08 (0%) | 🛒 Add to cart |
| 60 | $1.95 | $134.16 $116.96 (13%) | 🛒 Add to cart |
| 90 | $1.85 | $201.24 $166.84 (17%) | 🛒 Add to cart |
| 120 | $1.80 | $268.32 $215.86 (20%) | 🛒 Add to cart |
| 180 | $1.75 | $402.48 $315.62 (22%) | 🛒 Add to cart |
| 270 | $1.72
Best per pill | $603.72 $464.40 (23%) | 🛒 Add to cart |
Finast represents a significant advancement in the management of androgen-mediated dermatological and endocrine conditions. As a selective Type II 5α-reductase inhibitor, it specifically targets the enzymatic conversion of testosterone to dihydrotestosterone (DHT), the primary androgen implicated in pathological processes such as androgenetic alopecia and benign prostatic hyperplasia. Its mechanism offers a targeted therapeutic approach with well-established efficacy profiles across multiple clinical trials. This medication requires proper medical supervision and diagnostic confirmation before initiation to ensure appropriate patient selection and optimal therapeutic outcomes.
Features
- Contains finasteride as active pharmaceutical ingredient
- Selective Type II 5α-reductase inhibitor
- Available in 1mg and 5mg tablet formulations
- Film-coated tablets for ease of administration
- Manufactured under cGMP compliance
- Stable shelf life of 24 months from manufacturing date
- Bioequivalent to reference listed drug
- HPLC-certified purity (>99.8%)
Benefits
- Reduces serum DHT levels by approximately 70% within 24 hours of administration
- Prevents further miniaturization of hair follicles in androgenetic alopecia
- Improves hair count and hair weight measurements in clinical studies
- Reduces prostate volume in benign prostatic hyperplasia by 20-30%
- Improves urinary flow rates and symptom scores in BPH patients
- Provides long-term maintenance of therapeutic benefits with continuous use
Common use
Finast is primarily indicated for the treatment of male pattern hair loss (androgenetic alopecia) in men only, and for the treatment of symptomatic benign prostatic hyperplasia (BPH) in men with an enlarged prostate. It may be used as monotherapy or in combination with alpha-blockers for BPH management. The medication is not indicated for use in women or children, particularly women who are or may become pregnant due to risk of fetal abnormalities.
Dosage and direction
For androgenetic alopecia: 1mg orally once daily, with or without food. For benign prostatic hyperplasia: 5mg orally once daily, with or without food. Tablets should be swallowed whole with a glass of water. Clinical response may not be evident for 3-6 months in hair loss treatment and 6-12 months for BPH symptom improvement. Treatment must be continuous to maintain benefit; discontinuation will lead to reversal of effects within 12 months.
Precautions
Regular monitoring of prostate-specific antigen (PSA) levels is recommended for patients receiving 5mg dose for BPH. Hepatic impairment requires careful consideration and potential dose adjustment. Patients should be advised that decreased libido, erectile dysfunction, and ejaculation disorders may occur. Caution should be exercised in patients with obstructive uropathy. Women who are pregnant or may become pregnant should not handle crushed or broken tablets due to risk of absorption through skin.
Contraindications
Hypersensitivity to finasteride or any component of the formulation; use in women who are or may become pregnant; pediatric use; and patients with history of liver disease or abnormal liver function tests. Not recommended for patients with urinary retention or severe renal impairment without close medical supervision.
Possible side effects
Common adverse reactions (≥1% incidence) include: decreased libido (3.4%), erectile dysfunction (4.9%), ejaculation disorder (2.1%), decreased ejaculate volume (2.8%), breast tenderness and enlargement (0.5%). Less common effects include: testicular pain, depression, skin rash, and hypersensitivity reactions. Most sexual side effects are reversible upon discontinuation but may persist in some patients.
Drug interaction
Potential interactions with: anticoagulants (monitor INR), strong CYP3A4 inhibitors (may increase finasteride exposure), and other 5α-reductase inhibitors (avoid concomitant use). No clinically significant interactions with alpha-blockers, acetaminophen, or digoxin have been observed in clinical studies.
Missed dose
If a dose is missed, take it as soon as remembered unless it is almost time for the next dose. Do not double the dose to make up for a missed dose. Maintain regular dosing schedule for optimal therapeutic effect.
Overdose
No specific antidote exists. Single doses up to 400mg and multiple doses up to 80mg/day for three months have been administered without adverse effects. In case of suspected overdose, provide symptomatic and supportive treatment. Hemodialysis is not likely to be beneficial due to high protein binding.
Storage
Store at controlled room temperature (20-25°C/68-77°F). Keep in original container with lid tightly closed. Protect from light and moisture. Keep out of reach of children and pets. Do not use after expiration date printed on packaging.
Disclaimer
This information is for educational purposes only and does not constitute medical advice. Finast is a prescription medication that should be used only under the supervision of a qualified healthcare provider. Individual results may vary. Proper diagnosis and monitoring are essential for safe and effective use. Not all side effects are listed here; consult full prescribing information for complete details.
Reviews
Clinical studies demonstrate: 48% of men taking finasteride 1mg daily showed increased hair count at 12 months (N=1,553). In BPH trials, 5mg daily reduced prostate volume by 18% and improved peak urinary flow by 1.6 mL/sec at 12 months (N=3,040). Patient-reported outcomes indicate satisfaction with treatment efficacy, though some report persistent sexual side effects. Long-term studies show maintained efficacy with continuous use up to 5 years.